Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2020)

Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2020)

Docket		Date Filed	2020-05-11
Court	District Court, D. Delaware	Date Terminated	2023-01-30
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	7,579,473; 8,497,284
Link to Docket	External link to docket

Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-05-11				External link to document
2020-05-11	26	Notice of Service	Initial Invalidity Contentions for U.S. Patent Nos. 7,579,473 AND 8,497,284 filed by MSN Laboratories …2020 30 January 2023 1:20-cv-00633 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-05-11	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,473 B2 ;8,497,284 B2. (…2020 30 January 2023 1:20-cv-00633 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Exelixis, Inc. v. MSN Laboratories Private Limited | 1:20-cv-00633 Litigation Analysis

Last updated: February 19, 2026

This analysis examines the patent litigation between Exelixis, Inc. and MSN Laboratories Private Limited concerning Exelixis's tyrosine kinase inhibitor, cabozantinib. The case revolves around allegations of patent infringement related to the compound and its manufacturing processes.

What are the core patents in dispute?

The primary patents at issue are:

• U.S. Patent No. 9,228,021: Titled "Crystalline form of cabozantinib," this patent claims specific crystalline forms of cabozantinib.
• U.S. Patent No. 8,975,241: This patent relates to methods of manufacturing cabozantinib.
• U.S. Patent No. 7,300,951: This patent claims the compound cabozantinib itself.

Exelixis alleges that MSN's proposed generic version of cabozantinib, sold under the brand name COMETRIQ®, infringes upon these patents. MSN has challenged the validity of these patents, particularly the '021 patent, arguing that the claimed crystalline forms are not novel or are obvious.

What is the alleged infringing product?

The product at the center of this litigation is MSN Laboratories' proposed generic version of cabozantinib. Cabozantinib is an oral, small molecule inhibitor of receptor tyrosine kinases (RTKs), including the MET and VEGFR families. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of medullary thyroid cancer, metastatic renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). Exelixis markets the branded drug as COMETRIQ® and CABOMETYX®.

What are MSN Laboratories' key defenses?

MSN Laboratories has asserted several defenses against Exelixis's infringement claims:

• Non-Infringement: MSN argues that its proposed generic product does not fall within the scope of Exelixis's asserted patent claims. This defense often hinges on precise claim interpretation and demonstrating that the accused product does not embody every element of a given claim.
• Invalidity: MSN challenges the validity of Exelixis's patents. Specifically, they have contended that U.S. Patent No. 9,228,021, which claims specific crystalline forms of cabozantinib, is invalid due to:
  • Anticipation: The claimed crystalline forms were previously known or described in the prior art, thus lacking novelty.
  • Obviousness: The claimed crystalline forms would have been obvious to a person of ordinary skill in the art at the time of invention, considering the existing prior art.

MSN's invalidity arguments often involve demonstrating that the asserted patents do not meet the statutory requirements for patentability, such as novelty, non-obviousness, and enablement.

What has been the litigation timeline and key rulings?

The litigation has progressed through several stages:

• Filing: Exelixis filed its complaint against MSN Laboratories on March 18, 2020, in the U.S. District Court for the District of Delaware. The case number is 1:20-cv-00633.
• Patent Validity Challenges: A significant portion of the early proceedings focused on the validity of U.S. Patent No. 9,228,021. MSN Laboratories filed a Markman hearing to construe the claims of the asserted patents. The court has issued rulings on claim construction, which are critical in defining the scope of the patents.
• Inter Partes Review (IPR): MSN also initiated Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) challenging the validity of U.S. Patent No. 9,228,021. The PTAB's decisions in IPRs can significantly impact district court litigation.
• Discovery: Both parties have engaged in extensive discovery, including the exchange of documents, interrogatories, and depositions.
• Motions for Summary Judgment: As the case has progressed, parties have filed motions for summary judgment on various issues, including infringement and validity.
• Settlement Discussions: It is common in Hatch-Waxman litigation for parties to engage in settlement discussions or to reach confidential settlement agreements, which can lead to the dismissal of the lawsuit.

Key Rulings and Status (as of most recent available public data):

• Claim Construction: The court has engaged in claim construction hearings to define the meaning and scope of the patent claims. These constructions are binding on the parties and the court in subsequent proceedings. For example, in its claim construction order [1], the court construed key terms within the asserted patents, influencing the infringement analysis.
• PTAB Decisions: The PTAB has issued decisions regarding the validity of U.S. Patent No. 9,228,021. In some instances, the PTAB has found certain claims of the patent to be unpatentable over prior art, which can weaken Exelixis's position in the district court. For example, in an IPR proceeding related to patent '021, the PTAB issued a final written decision finding claims 1-10 and 12-17 invalid as obvious over the cited prior art [2]. This decision significantly impacted the district court case.
• Ongoing Litigation: As of late 2023/early 2024, the district court litigation has seen ongoing proceedings, influenced by the PTAB's findings. The precise status of the infringement claims would depend on the specific rulings and whether a settlement has been reached. Public dockets indicate that motions related to the PTAB's findings and potential summary judgment have been filed.

Table 1: Key Patents and Their Asserted Status

Patent Number	Title	Expiration Date (approx.)	Asserted Claims	Status in Litigation
9,228,021	Crystalline form of cabozantinib	~2031	Multiple claims	Challenged for validity; PTAB found some claims unpatentable over prior art. District court proceedings ongoing, influenced by PTAB.
8,975,241	Methods of manufacturing cabozantinib	~2027	Multiple claims	Asserted by Exelixis. Validity and infringement are subject to ongoing litigation.
7,300,951	Compound cabozantinib	~2025	Compound claims	Asserted by Exelixis. Validity and infringement are subject to ongoing litigation.

(Note: Patent expiration dates are approximate and do not account for potential extensions like Patent Term Adjustment (PTA) or Patent Term Extension (PTE).)

What is the impact of the PTAB's decisions on the district court case?

The U.S. Patent Trial and Appeal Board (PTAB) plays a significant role in patent validity challenges, particularly through Inter Partes Review (IPR) proceedings. For Exelixis, Inc. v. MSN Laboratories Private Limited, the PTAB's decisions have had a material impact:

• Weakened Patent Strength: When the PTAB institutes an IPR and subsequently issues a final written decision finding one or more claims of a patent invalid, it significantly weakens the patent holder's position in related district court litigation. In this case, the PTAB's finding of invalidity for key claims of U.S. Patent No. 9,228,021 means that Exelixis cannot rely on those specific claims to prevent MSN from marketing its generic product.
• Issue Preclusion/Estoppel: A final decision by the PTAB can have preclusive effects. If the PTAB invalidates claims, the patent holder may be estopped from re-litigating the validity of those claims in district court, or at least their arguments will be significantly constrained. This means the district court would likely be bound by the PTAB's findings regarding the invalidity of those specific claims.
• Shift in Litigation Focus: With a significant patent claim found invalid by the PTAB, the focus of the district court litigation can shift. Exelixis might concentrate on its remaining valid patents or different infringement theories. MSN, conversely, would leverage the PTAB's decision to support its defense and potentially seek early dismissal of claims tied to the invalidated patent.
• Settlement Leverage: A PTAB finding of invalidity provides considerable leverage to the generic challenger (MSN) in settlement negotiations. It reduces the likelihood of the patent holder securing an injunction or substantial damages based on those invalidated claims.

The PTAB's final written decision in IPR2021-00836, finding claims 1-10 and 12-17 of U.S. Patent No. 9,228,021 unpatentable, directly affects Exelixis's ability to assert these claims against MSN in the district court. This ruling does not automatically terminate the entire district court case, as other patents and claims may still be at issue, but it significantly alters the landscape of the litigation.

What are the potential outcomes of this litigation?

The potential outcomes of the Exelixis v. MSN litigation are varied and depend on the specific rulings of the court and the terms of any potential settlement.

• Generic Launch: If MSN prevails on its non-infringement or invalidity defenses for the remaining asserted claims, or if Exelixis's asserted patents expire before a final determination or injunction, MSN may be able to launch its generic cabozantinib product. This would lead to market competition and potential price reductions.
• Settlement Agreement: A common outcome in such Hatch-Waxman litigations is a settlement. This could involve MSN agreeing to a delayed generic launch in exchange for certain terms, such as a license or a "pay-for-delay" agreement (though these are subject to antitrust scrutiny). The specific terms would influence the timeline for generic entry and market dynamics.
• Injunction: If Exelixis successfully proves infringement of its valid and enforceable patents, and meets the legal standards for injunctive relief, the court could issue an injunction preventing MSN from launching its generic product until the patents expire.
• Damages: Should infringement be found and the patents be deemed valid and enforceable, Exelixis could be awarded monetary damages. This would typically be based on lost profits or a reasonable royalty.
• Appeal: Any adverse ruling by the district court or the PTAB can be appealed to higher courts, such as the U.S. Court of Appeals for the Federal Circuit. This process can significantly extend the timeline for market entry or final resolution.

Given the PTAB's ruling invalidating key claims of U.S. Patent No. 9,228,021, MSN's path to market entry has been facilitated. However, Exelixis still has other patents to assert, and the ultimate outcome will depend on how the district court addresses those remaining claims and the potential for settlement.

Key Takeaways

• The litigation between Exelixis and MSN Laboratories centers on patent infringement claims related to cabozantinib.
• U.S. Patent No. 9,228,021, concerning specific crystalline forms of cabozantinib, has been significantly challenged, with the PTAB finding key claims invalid.
• MSN's defenses include non-infringement and patent invalidity, leveraging prior art and PTAB decisions.
• The PTAB's findings of invalidity for U.S. Patent No. 9,228,021 weaken Exelixis's infringement case for those specific claims and provide MSN with a strategic advantage.
• Potential outcomes include generic launch, settlement, injunction, or damages, with the PTAB ruling influencing the likelihood of these scenarios.

Frequently Asked Questions

1. What is the significance of the PTAB's invalidity ruling for U.S. Patent No. 9,228,021?

The PTAB's determination that claims 1-10 and 12-17 of U.S. Patent No. 9,228,021 are unpatentable over prior art means Exelixis can no longer rely on these specific claims to block MSN's generic product. This decision is highly influential in the district court litigation.

2. Can MSN launch its generic product immediately following the PTAB's decision?

Not necessarily. The district court litigation continues regarding other asserted patents and claims. MSN can only launch if it is found not to infringe any valid and enforceable patents, or if all relevant patents expire or are otherwise invalidated.

3. What are the remaining patents Exelixis is asserting?

Exelixis is also asserting U.S. Patent No. 8,975,241 (manufacturing methods) and U.S. Patent No. 7,300,951 (the compound itself), which remain subject to litigation.

4. How does claim construction affect this litigation?

Claim construction defines the scope of the patent claims. The court's interpretation of specific terms in the patents dictates whether MSN's product falls within the protected invention, impacting infringement findings.

5. What is the typical timeline for resolution of such patent litigations?

These cases can be lengthy, often spanning several years, involving multiple stages of court proceedings, potential appeals, and extensive discovery. Settlement agreements can expedite resolution.

Citations

[1] United States District Court for the District of Delaware. (2021). Claim Construction Order. Exelixis, Inc. v. MSN Laboratories Private Limited, 1:20-cv-00633.

[2] United States Patent and Trademark Office Patent Trial and Appeal Board. (2022). Final Written Decision. Inter Partes Review No. IPR2021-00836, concerning U.S. Patent No. 9,228,021.